| scholarly article | Q13442814 |
| P50 | author | Robert H. Purcell | Q2157414 |
| Peter Schuck | Q44237726 | ||
| Sutee Yoksan | Q114411207 | ||
| P2093 | author name string | Ching-Juh Lai | |
| Ana P Goncalvez | |||
| Inna Gorshkova | |||
| Olivia Donau | |||
| Carrie Roll | |||
| Cheng-Hsin Chien | |||
| Kamolchanok Tubthong | |||
| Sy-Dar Wang | |||
| P2860 | cites work | Monoclonal antibody-mediated enhancement of dengue virus infection in vitro and in vivo and strategies for prevention | Q24684689 |
| Structure of dengue virus: implications for flavivirus organization, maturation, and fusion | Q24736810 | ||
| Mutational Evidence for an Internal Fusion Peptide in Flavivirus Envelope Protein E | Q27469788 | ||
| Monoclonal Antibodies That Bind to Domain III of Dengue Virus E Glycoprotein Are the Most Efficient Blockers of Virus Adsorption to Vero Cells | Q27469935 | ||
| A functional epitope determinant on domain III of the Japanese encephalitis virus envelope protein interacted with neutralizing-antibody combining sites | Q27473104 | ||
| Development of a humanized monoclonal antibody with therapeutic potential against West Nile virus | Q27473186 | ||
| Isolation and Characterization of Human Monoclonal Antibodies from Individuals Infected with West Nile Virus | Q27473288 | ||
| Origin and Evolution of Japanese Encephalitis Virus in Southeast Asia | Q27473338 | ||
| Cryptic Properties of a Cluster of Dominant Flavivirus Cross-Reactive Antigenic Sites | Q27477542 | ||
| Crystal Structure of West Nile Virus Envelope Glycoprotein Reveals Viral Surface Epitopes | Q27477610 | ||
| Use of surface plasmon resonance to probe the equilibrium and dynamic aspects of interactions between biological macromolecules. | Q41549028 | ||
| Antigenic and genetic variations among Japanese encephalitis virus strains belonging to genotype 1. | Q42654742 | ||
| Characterization of monoclonal antibody-escape mutants of tick-borne encephalitis virus with reduced neuroinvasiveness in mice | Q42981029 | ||
| Mutations in the envelope protein of Japanese encephalitis virus affect entry into cultured cells and virulence in mice | Q42982028 | ||
| Passive protection of mice, goats, and monkeys against Japanese encephalitis with monoclonal antibodies | Q42989454 | ||
| Rapid focus reduction neutralization test of Japanese encephalitis virus in microtiter system. Brief report | Q42994529 | ||
| New initiatives for the control of Japanese encephalitis by vaccination: minutes of a WHO/CVI meeting, Bangkok, Thailand, 13-15 October 1998. | Q42998699 | ||
| Elucidation of the topography and determination of the protective epitopes on the E glycoprotein of Saint Louis encephalitis virus by passive transfer with monoclonal antibodies | Q43030485 | ||
| The appearance of a second genotype of Japanese encephalitis virus in the Australasian region. | Q43036051 | ||
| Murray Valley Encephalitis Virus Envelope Protein Antigenic Variants with Altered Hemagglutination Properties and Reduced Neuroinvasiveness in Mice | Q43038176 | ||
| The domain III fragment of Japanese encephalitis virus envelope protein: mouse immunogenicity and liposome adjuvanticity | Q43048619 | ||
| Binding of an antibody mimetic of the human low density lipoprotein receptor to apolipoprotein E is governed through electrostatic forces. Studies using site-directed mutagenesis and molecular modeling | Q73509838 | ||
| Single dose of SA 14-14-2 vaccine provides long-term protection against Japanese encephalitis: a case-control study in Nepalese children 5 years after immunization. drjbtandan@yahoo.com | Q80374875 | ||
| A ligand-binding pocket in the dengue virus envelope glycoprotein | Q27477685 | ||
| Antibody Recognition and Neutralization Determinants on Domains I and II of West Nile Virus Envelope Protein | Q27477718 | ||
| Processing of Capsid Protein by Cathepsin L Plays a Crucial Role in Replication of Japanese Encephalitis Virus in Neural and Macrophage Cells | Q27481023 | ||
| Induction of Epitope-Specific Neutralizing Antibodies against West Nile Virus | Q27484980 | ||
| Epitope Determinants of a Chimpanzee Dengue Virus Type 4 (DENV-4)-Neutralizing Antibody and Protection against DENV-4 Challenge in Mice and Rhesus Monkeys by Passively Transferred Humanized Antibody | Q27485025 | ||
| Type- and Subcomplex-Specific Neutralizing Antibodies against Domain III of Dengue Virus Type 2 Envelope Protein Recognize Adjacent Epitopes | Q27485031 | ||
| Carboxy-terminally truncated dengue virus envelope glycoproteins expressed on the cell surface and secreted extracellularly exhibit increased immunogenicity in mice | Q27486177 | ||
| The Stoichiometry of Antibody-Mediated Neutralization and Enhancement of West Nile Virus Infection | Q27488224 | ||
| Structural basis of a flavivirus recognized by its neutralizing antibody: solution structure of the domain III of the Japanese encephalitis virus envelope protein | Q27641947 | ||
| The envelope glycoprotein from tick-borne encephalitis virus at 2 A resolution | Q27730234 | ||
| SWISS-MODEL and the Swiss-PdbViewer: an environment for comparative protein modeling | Q27860614 | ||
| UCSF Chimera--a visualization system for exploratory research and analysis | Q27860666 | ||
| Emerging flaviviruses: the spread and resurgence of Japanese encephalitis, West Nile and dengue viruses | Q27860800 | ||
| ProMod and Swiss-Model: Internet-based tools for automated comparative protein modelling | Q29617090 | ||
| Structural basis of West Nile virus neutralization by a therapeutic antibody | Q29618168 | ||
| Variable surface epitopes in the crystal structure of dengue virus type 3 envelope glycoprotein | Q29618169 | ||
| Japanese encephalitis vaccines: current vaccines and future prospects | Q31087320 | ||
| A new genotype of Japanese encephalitis virus from Indonesia | Q31161155 | ||
| Identification of chimpanzee Fab fragments by repertoire cloning and production of a full-length humanized immunoglobulin G1 antibody that is highly efficient for neutralization of dengue type 4 virus | Q33201423 | ||
| Chimpanzee Fab fragments and a derived humanized immunoglobulin G1 antibody that efficiently cross-neutralize dengue type 1 and type 2 viruses | Q33208947 | ||
| Construction of human Fab (gamma1/kappa) library and identification of human monoclonal Fab possessing neutralizing potency against Japanese encephalitis virus | Q33288231 | ||
| An outbreak of Japanese encephalitis in the Torres Strait, Australia, 1995. | Q34734760 | ||
| Occupancy and mechanism in antibody-mediated neutralization of animal viruses | Q34788252 | ||
| Antigenic structure of flavivirus proteins | Q35616815 | ||
| Probing the functional heterogeneity of surface binding sites by analysis of experimental binding traces and the effect of mass transport limitation | Q35633065 | ||
| Japanese Encephalitis Outbreak, India, 2005. | Q35805777 | ||
| Neutralizing recombinant human antibodies to a conformational V2- and CD4-binding site-sensitive epitope of HIV-1 gp120 isolated by using an epitope-masking procedure. | Q36677139 | ||
| Epitope determinants of a chimpanzee Fab antibody that efficiently cross-neutralizes dengue type 1 and type 2 viruses map to inside and in close proximity to fusion loop of the dengue type 2 virus envelope glycoprotein | Q37596501 | ||
| Locus of a virus neutralization epitope on the Japanese encephalitis virus envelope protein determined by use of long PCR-based region-specific random mutagenesis | Q39269567 | ||
| Yellow fever virus envelope protein has two discrete type-specific neutralizing epitopes | Q39416089 | ||
| Antigenic variants of yellow fever virus with an altered neurovirulence phenotype in mice | Q39416099 | ||
| Characterization of an antigenic site that contains a dominant, type-specific neutralization determinant on the envelope protein domain III (ED3) of dengue 2 virus | Q40441111 | ||
| An evaluation of dengue type-2 inactivated, recombinant subunit, and live-attenuated vaccine candidates in the rhesus macaque model | Q40504189 | ||
| Antibody responses against wild-type yellow fever virus and the 17D vaccine strain: characterization with human monoclonal antibody fragments and neutralization escape variants | Q40507496 | ||
| A recombinant envelope protein vaccine against West Nile virus | Q40507551 | ||
| High-level expression and one-step purification of recombinant dengue virus type 2 envelope domain III protein in Escherichia coli | Q40543711 | ||
| Chimeric live, attenuated vaccine against Japanese encephalitis (ChimeriVax-JE): phase 2 clinical trials for safety and immunogenicity, effect of vaccine dose and schedule, and memory response to challenge with inactivated Japanese encephalitis anti | Q40548538 | ||
| Detection of west Nile and Japanese encephalitis viral genome sequences in cerebrospinal fluid from acute encephalitis cases in Karachi, Pakistan | Q40708279 | ||
| Increased immunogenicity and protective efficacy in outbred and inbred mice by strategic carboxyl-terminal truncation of Japanese encephalitis virus envelope glycoprotein | Q40720762 | ||
| Phylogenetic analysis of Japanese encephalitis virus: envelope gene based analysis reveals a fifth genotype, geographic clustering, and multiple introductions of the virus into the Indian subcontinent | Q40780011 | ||
| Protection of mice against Japanese encephalitis virus by passive administration with monoclonal antibodies | Q40781926 | ||
| Lethal 17D yellow fever encephalitis in mice. I. Passive protection by monoclonal antibodies to the envelope proteins of 17D yellow fever and dengue 2 viruses | Q40810691 | ||
| P433 | issue | 14 | |
| P921 | main subject | antibody | Q79460 |
| encephalitis | Q199615 | ||
| monoclonal antibody | Q422248 | ||
| Japanese encephalitis | Q738292 | ||
| chimpanzee | Q4126704 | ||
| Japanese encephalitis virus | Q19838331 | ||
| P304 | page(s) | 7009-7021 | |
| P577 | publication date | 2008-05-14 | |
| P1433 | published in | Journal of Virology | Q1251128 |
| P1476 | title | Humanized monoclonal antibodies derived from chimpanzee Fabs protect against Japanese encephalitis virus in vitro and in vivo | |
| P478 | volume | 82 |
| Q30557856 | A comparison of binding surfaces for SPR biosensing using an antibody-antigen system and affinity distribution analysis. |
| Q34123956 | Analysis of epitopes on dengue virus envelope protein recognized by monoclonal antibodies and polyclonal human sera by a high throughput assay |
| Q34980404 | CD8+ T cells complement antibodies in protecting against yellow fever virus |
| Q42997595 | Chimeric antibodies against tick-borne encephalitis virus. |
| Q34471908 | Chimpanzees as an animal model for human norovirus infection and vaccine development. |
| Q35854520 | Complex phenotypes in mosquitoes and mice associated with neutralization escape of a Dengue virus type 1 monoclonal antibody |
| Q37750121 | Correlates of protection induced by vaccination |
| Q27676100 | Crystal Structure of the Japanese Encephalitis Virus Envelope Protein |
| Q59349995 | Crystal structure of Usutu virus envelope protein in the pre-fusion state |
| Q42978692 | Design and characterization of polytope construct with multiple B and TH epitopes of Japanese encephalitis virus |
| Q34260219 | Development of a humanized antibody with high therapeutic potential against dengue virus type 2 |
| Q37785368 | Domain III peptides from flavivirus envelope protein are useful antigens for serologic diagnosis and targets for immunization |
| Q47548498 | Engineering of Fc Fragments with Optimized Physicochemical Properties Implying Improvement of Clinical Potentials for Fc-Based Therapeutics |
| Q38017388 | Flaviviruses and flavivirus vaccines |
| Q37728833 | Generation and characterization of the human neutralizing antibody fragment Fab091 against rabies virus |
| Q36033286 | Generation of Recombinant Antibodies Against Toxins and Viruses by Phage Display for Diagnostics and Therapy. |
| Q39668466 | Genotype-specific neutralization and protection by antibodies against dengue virus type 3. |
| Q37336440 | High-avidity and potently neutralizing cross-reactive human monoclonal antibodies derived from secondary dengue virus infection |
| Q27488791 | Human Monoclonal Antibodies against West Nile Virus Induced by Natural Infection Neutralize at a Postattachment Step |
| Q59350579 | Humanized Mouse Models for the Study of Infection and Pathogenesis of Human Viruses |
| Q35982791 | Identification of human neutralizing antibodies that bind to complex epitopes on dengue virions |
| Q35141448 | Immune correlates of protection against yellow fever determined by passive immunization and challenge in the hamster model |
| Q36760059 | JE-ADVAX vaccine protection against Japanese encephalitis virus mediated by memory B cells in the absence of CD8(+) T cells and pre-exposure neutralizing antibody |
| Q58999704 | Japanese Encephalitis Virus Generated Neurovirulence, Antigenicity, and Host Immune Responses |
| Q42223323 | Japanese encephalitis virus expands regulatory T cells by increasing the expression of PD-L1 on dendritic cells |
| Q27010434 | Japanese encephalitis: the virus and vaccines |
| Q54265465 | Mouse and Human Monoclonal Antibodies Protect against Infection by Multiple Genotypes of Japanese Encephalitis Virus. |
| Q36254692 | Neutralization of Japanese Encephalitis Virus by heme-induced broadly reactive human monoclonal antibody |
| Q26862449 | Novel approaches and challenges to treatment of central nervous system viral infections |
| Q34982611 | Pivotal role of antibody and subsidiary contribution of CD8+ T cells to recovery from infection in a murine model of Japanese encephalitis |
| Q24289014 | Possible future monoclonal antibody (mAb)-based therapy against arbovirus infections |
| Q27489893 | Progress on the development of therapeutics against West Nile virus |
| Q36023082 | Recombinant antibodies for diagnostics and therapy against pathogens and toxins generated by phage display. |
| Q40045437 | Regulatory considerations in development of vaccines to prevent disease caused by Chikungunya virus |
| Q27488364 | Structural Insights into the Mechanisms of Antibody-Mediated Neutralization of Flavivirus Infection: Implications for Vaccine Development |
| Q34120070 | Structure and function analysis of therapeutic monoclonal antibodies against dengue virus type 2. |
| Q27674868 | Structure of the St. Louis Encephalitis Virus Postfusion Envelope Trimer |
| Q24289393 | Structure of yellow fever virus envelope protein domain III |
| Q27491317 | The Development of Therapeutic Antibodies That Neutralize Homologous and Heterologous Genotypes of Dengue Virus Type 1 |
| Q37448171 | The human immune response to Dengue virus is dominated by highly cross-reactive antibodies endowed with neutralizing and enhancing activity |
| Q34037127 | The neutralizing human recombinant antibodies to pathogenic Orthopoxviruses derived from a phage display immune library. |
| Q38644638 | Use of fluorescence-detected sedimentation velocity to study high-affinity protein interactions |
Search more.